Atara Biotherapeutics, Inc. (ATRA) Investor Relations Documents

Atara Biotherapeutics, Inc. (ATRA) investor relations documents from the company's IR site: 2 presentations, 38 press releases; latest deck 2024-11-12. Read in-app with summaries. First-party data.

View Presentation: Atara Biotherapeutics Q3 2024 investor update: Tab-cel U.S. BLA PDUFA date is January 15, 2025, with cash runway extending into 2027.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-12Press releaseAtara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational Progress
2026-06-12Press releaseAtara Biotherapeutics Announces Changes to Its Board of Directors
2026-05-12Press releaseAtara Biotherapeutics Announces First Quarter 2026 Financial Results and Operational Progress
2026-05-12Press releasePDF
2026-05-07Press releaseAtara Biotherapeutics Provides Regulatory Update on Tabelecleucel
2026-03-16Press releasePDF
2026-03-12Press releaseAtara Biotherapeutics Provides Regulatory Update on Tabelecleucel
2026-03-03Press releaseAtara Biotherapeutics Provides Regulatory Update on Tabelecleucel
2026-02-23Press releaseAtara Biotherapeutics Provides a Business Update
2026-02-08Press releaseAtara Biotherapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Operational Progress
2026-01-09Press releaseAtara Biotherapeutics Provides Regulatory and Business Update on EBVALLO™ (tabelecleucel)
2025-11-12Press releaseAtara Biotherapeutics Announces Third Quarter Financial Results and Operational Progress
2025-11-12Press releasePDF
2025-09-03Press releaseAtara Biotherapeutics Announces Changes to Its Board of Directors
2025-08-11Press releasePDF
2025-05-15Press releasePDF
2025-03-07Press releasePDF
2025-02-08Press releaseAtara Biotherapeutics Provides Regulatory Updates on EBVALLO™ (tabelecleucel)
2024-11-13Press releaseAtara Biotherapeutics to Participate at the Stifel 2024 Healthcare Conference
2024-11-12PresentationView Presentation
2024-11-12Press releasePDF
2024-11-05Press releaseAtara Biotherapeutics to Announce Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
2024-09-09PresentationH.C. Wainwright 26th Annual Global Investment Conference
2024-08-12Press releasePDF
2024-08-08Press releaseAtara Biotherapeutics Announces Plans to Submit Tab-cel® BLA in Q2 2024 Following FDA Agreement on Comparability
2024-05-09Press releasePDF
2024-04-05Press releaseAtara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2024-03-28Press releasePDF
2024-02-08Press releaseAtara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress
2023-11-01Press releasePDF
2023-08-08Press releasePDF
2023-08-01Press releaseAtara Biotherapeutics to Announce Second Quarter 2023 Financial Results on Tuesday, August 8, 2023
2023-05-08Press releasePDF
2023-05-01Press releaseAtara Biotherapeutics to Announce First Quarter 2023 Financial Results on Monday, May 8, 2023
2023-02-08Press releasePDF
2023-02-08Press releaseAtara Biotherapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Operational Progress
2023-02-06Press releaseAtara Biotherapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results on Wednesday, February 8, 2023
2022-11-08Press releasePDF
2022-11-01Press releaseAtara Biotherapeutics to Announce Third Quarter 2022 Financial Results on Tuesday, November 8, 2022
2022-08-08Press releasePDF

ATRA overview · ATRA earnings · ATRA financials · ATRA KPIs · ATRA ownership · ATRA peers · ATRA filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.